Acta Med. 2007, 50: 113-118

https://doi.org/10.14712/18059694.2017.66

Addition of Rituximab Significantly Improves Outcomes in Patients with Diffuse Large B-cell Lymphoma – a Single-center, Retrospective Study

David Beladaa, Lukáš Smoleja, Monika Hrudkováa, Pavla Štěpánkováa, Alice Sýkorováa, Pavel Žáka, Jiří Bukačb, Jaroslav Malýa

aCharles University in Prague, Faculty of Medicine and University Hospital in Hradec Králové, 2nd Department of Medicine, Division of Clinical Hematology, Hradec Králové, Czech Republic
bCharles University in Prague, Faculty of Medicine and University Hospital in Hradec Králové, Department of Medical Biophysics, Hradec Králové, Czech Republic

Received March 1, 2007
Accepted May 1, 2007

References

1. Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N. Targeted anticancer therapy using rituximab, a chimeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin’s B-cell lymphoma. Biochem Soc Trans 1997; 25: 705–8. <https://doi.org/10.1042/bst0250705>
2. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104:2635–42. <https://doi.org/10.1182/blood-2004-03-1110>
3. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippstein D, Hiddemann W, Castelino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non- Hodgkin’s lymphomas. J Clin Oncol 1999; 17:1244. Erratum in: J Clin Oncol 2000;18:2351. <https://doi.org/10.1200/JCO.1999.17.4.1244>
4. Coiffier B. Increasing chemotherapy intensity in aggressive lymphomas: a renewal? J Clin Oncol 2003; 21:2457–9. <https://doi.org/10.1200/JCO.2003.93.116>
5. Coiffier B. Effective immunochemotherapy for aggressive non-Hodgkin’s lymphoma. Semin Oncol 2004; 31(1 Suppl. 2):7–11. <https://doi.org/10.1053/j.seminoncol.2003.12.003>
6. Coiffier B. Treatment of diffuse large B-cell lymphoma. Curr Hematol Rep 2005; 4:7–14.
7. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F. Rituximab (anti- CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927–32.
8. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235–42. <https://doi.org/10.1056/NEJMoa011795>
9. Devita VT Jr, Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1975; 1:248–50. <https://doi.org/10.1016/S0140-6736(75)91142-3>
10. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005; 23:4117–26. <https://doi.org/10.1200/JCO.2005.09.131>
11. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA JR, Miller TP. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin’s lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol 1994; 5(Suppl. 2):91–95. <https://doi.org/10.1093/annonc/5.suppl_2.S91>
12. Grillo-Lopez AJ. Rituximab (Rituxan/MabThera): the first decade (1993–2003). Expert Rev Anticancer Ther 2003; 3:767–79. <https://doi.org/10.1586/14737140.3.6.767>
13. Grillo-Lopez AJ. Rituximab: an insider’s historical perspective. Semin Oncol 2000; 27(6 Suppl. 12):9–16.
14. Habermann TM, Weller EA, Morrison VA, Cassileth PA, Cohn JB, Dakhil SR, Gascoyne RD, Woda B, Fisher RI, Peterson BA, Horning SJ. Phase III trial of rituximab- CHOP (R-CHOP) vs. CHOP with second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 102(Suppl.):6a (abstract 8).
15. Habermann TM, Weller EA, Morrison WA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SH, Woda B, Fisher RI, Peterson BA, Horning SJ. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24:3121–7. <https://doi.org/10.1200/JCO.2005.05.1003>
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457–81. <https://doi.org/10.1080/01621459.1958.10501452>
17. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a fourdose treatment program. J Clin Oncol 1998; 16:2825–33. <https://doi.org/10.1200/JCO.1998.16.8.2825>
18. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M;Mabthera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7:379–91. <https://doi.org/10.1016/S1470-2045(06)70664-7>
19. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M: German High-Grade Non-Hodgkin’s Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104:634–41. <https://doi.org/10.1182/blood-2003-06-2095>
20. Pfreundschuh M, Kloess M, Schmits R, Zeynalova S, Lengfelder E, Franke A, Steinhauer H, Reiser M, Clemens M, Nickenig C, De Wit M, Hoffmann M, Mertelsmann R, Metzner B, Ho A, Truemper L, Eimermacher H, Mergenthaler H, Liersch R, Duehrsen U, Balleisen L, Hartmann F, Poeschel V, Schmitz N, Loeffler M. Six, not eight cycles of bi-weekly CHOP with rituximab (R CHOP- 14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Blood 2005; 106(Suppl.): 9a (abstract 13).
21. Pytlík R, Trněný M, Belada D, Kubáčková K, Vášová I, Jankovská M, Klener P, for the Czech Lymphoma Study Group. Treatment of 101 high-risk aggressive Bcell lymphoma patients with MegaCHOP-BEAM regimen ± rituximab: the evolution of the concept. Ann Oncol 2005; 165(Suppl. 5):v175–v176 (abstract 473).
22. Raefsky EL, Greco FA, Spigel DR, Doss HH, Farley C, Saez R, Kommor M, Hainsworth JD. Brief duration rituximab(R)/chemotherapy (CNOP or CVP) followed by maintenance rituximab in elderly/poor performance status patients (pts) with diffuse large B-cell lymphoma (DLBCL): a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2006; 24(Suppl. 128S) (abstract 7577).
23. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O’Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23:5027–33. <https://doi.org/10.1200/JCO.2005.09.137>
24. Shah GD, Deangelis LM. Treatment of primary central nervous system lymphoma. Hematol Oncol Clin North Am 2005; 19:611–27. <https://doi.org/10.1016/j.hoc.2005.05.002>
25. Schmits R, Schmitz N, Pfreundschuh M;German High-Grade Non-Hodgkin’s Lymphoma Study Group. The best treatment for diffuse large B-cell lymphoma: a German perspective. Oncology (Williston Park) 2005; 19(4 Suppl. 1);16–22.
26. Stein H. The new WHO classification of malignant lymphoma. After “REAL” a further step on the road to a worldwide consensus. Pathologe 2000; 21:101–5. <https://doi.org/10.1007/s002920050377>
27. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 2005; 46:1569–73. <https://doi.org/10.1080/10428190500217312>
28. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non- Hodgkin’s lymphoma. J Clin Oncol 2001; 19:389–97. <https://doi.org/10.1200/JCO.2001.19.2.389>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive